Form 4: Denali Therapeutics Director Sells Shares
Insider Transaction (Form 4)
Nancy Thornberry, a Director of Denali Therapeutics Inc., sold 11,439 shares of common stock on September 2, 2026.
Summary
- Open-market sale: disposed of 10,824 Common Stock at $22.85 ($247,328) on September 2, 2026; holds 20,301 after (Direct).
- Open-market sale: disposed of 615 Common Stock at $23.74 ($14,600) on September 2, 2026; holds 19,686 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $261,928 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Nancy Thornberry — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-02 | Open-market sale | Common Stock | 10,824 | $23 | $247.3K | 20,301 |
| 2026-09-02 | Open-market sale | Common Stock | 615 | $24 | $14.6K | 19,686 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-02 | Open-market sale (10,824 shares) |
| 2026-09-02 | Open-market sale (615 shares) |
Keywords
insider transaction, Form 4, DNLI, Denali Therapeutics Inc., bearish, Nancy Thornberry
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.